期刊文献+

超声评价高效抗逆转录病毒疗法对艾滋病患者颈动脉弹性的影响 被引量:6

Evaluate the effect of highly active antiretroviral therapy on carotid artery stiffness by ultrasound in acquired immune deficiency syndrome patients
原文传递
导出
摘要 【摘要1目的探讨我国目前艾滋病(acquired immune deficiencysyndrome,AIDS)患者采用的一线高效抗逆转录病毒疗法(highlyactiveantiretroviraltherapy,HAART)治疗方案对AIDS患者颈动脉弹性的影响。方法选取AIDS患者100例,非治疗组、HAART治疗组患者各50例,健康志愿者50例为对照组,行右侧颈动脉内一中膜厚度(IMT)测量和动脉弹性测量。结果对照组、AIDS治疗组和非治疗组三组间IMT比较差异无统计学意义(P〉0.05);与对照组比较,AIDS治疗组和非治疗组颈动脉顺应性(CC)降低,僵硬度(8)、脉搏波传导速度(PwV)升高,差异具有统计学意义(P〈0.05);AIDS治疗组和非治疗组间IMT、CC、8、PwV差异无统计学意义(P〉0.05)。结论AIDS患者在未出现颈动脉IMT增厚的早期阶段,其弹性功能已减低。目前国内AIDS治疗采用的一线HAART治疗方案,在用药依从性好(80%以上)、无严重其他系统并发症的轻症AIDS患者中较长期应用以来,未见对其动脉弹性功能造成明显不良影响。 Objective To evaluate the effect of highly active antiretroviral therapy (HAART) on carotid artery stiffness in acquired immune deficiency syndrome (AIDS) patients. Methods 100 AIDS patients were enrolled in this study, and were divided into un-therapy group( n = 50) and HAART group (n = 50),50 cases healthy people as control group. Carotid artery QIMT and QAS was examined and the intima media thiekness(IMT) and stiffness parameters were obtained. Results There was no statistically significance of IMT in three groups( P ~0.05). Comprare to the control group, compliance coefficent(CC) of un-therapy group and HAART group were decreased, stiffness 13 and pulse wave velocity(PWV) were increased,and there were statistically differences( P d0.05). But between un-therapy group and H AART group,there were no statistically differences of stiffness parameters( P ~0.05). Conclusions The carotid artery stiffness had reduced before IMT thicken in AIDS patients. There was no association between first- line HAART and carotid artery stiffness in mild AIDS patients.
出处 《中华超声影像学杂志》 CSCD 北大核心 2014年第1期24-26,共3页 Chinese Journal of Ultrasonography
关键词 超声检查 颈动脉 弹性 获得性免疫缺陷综合征 抗逆转录病毒治疗 高效 Ultrasonography Carotid artery Elasticity Acquired immunodeficiency syndrome Antiretroviral therapy, highly active
  • 相关文献

参考文献7

  • 1Currier JS,Kendall MA,Henry WK,et al.Progression of carotidartery intima-media thickening in HIV-infected and uninfectedadults[J].AIDS,2007,21:1137-1145.
  • 2张学祥,刘惜年,黄琴,沈芳,王江蓉,孙洪清,卢洪洲.35例艾滋病患者高效联合抗反转录病毒治疗后血脂代谢及颈动脉中层厚度的研究[J].微生物与感染,2006,1(2):105-106. 被引量:9
  • 3Lorenz MW,Stephan C,Harmjanz A,et al.Both long-term HIVinfection and highly active antiretroviral therapy are independentrisk factors for early carotid atherosclerosis[J].Atherosclerosis,2008,196:720-726.
  • 4Seaberg EC,Benning L,Sharrett AR,et al.Association betweenHIV infection and stiffness of the common carotid artery[J].Stroke,2010,10:2163-2170.
  • 5Dube MP,Lipshultz SE,Fichtenbaum CJ,et al.Effects of HIVinfection and antiretroviral therapy on the heart and vasculature[J].Circulation,2008,118:e36-40.
  • 6Farrugia PM,Lucariello R,Coppola JT.Human immunodeficiencyvirus and atherosclerosis[J].Cardiol Rev,2009,17:211-215.
  • 7Strategies for management of antireroviral terapy(SMART)study group; Lundgren JD,Babiker A,EI-Sadr W,et al.Inferiorclinical outcome of the CD4 + cell count-guided antiretroviraltreatment interruption strateyy in the SMART study:role of CD4 + cell counts and HIV RNA levels during follow-up[J].J Infect Dis,2008,197:1145-1155.

二级参考文献10

  • 1Das S. HIV and increased risk of cardiovascular diseases. Sex Health,2005,2:219-221
  • 2Zareba KM, Miller TL, Lipshuhz SE. Cardiovascular disease and toxieities related to HIV infection and its therapies. Expert Opin Drug Saf,2005,4:1017 - 1025
  • 3Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTl-based therapy in the Swiss HIV cohort study. Antivir Ther,2005, 10:585-591
  • 4Umeh OC, Currier JS. Lipids metabolie syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curt HIV/AIDS Rep,2005,2:132 - 139
  • 5Spieker LE, Karadag B, Binggeli C, et al. Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection. Heart Vessels,2005,20:171 - 174
  • 6Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med, 2005,6 : 396 - 402
  • 7Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS, 2005, 19:1103-1105
  • 8Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidemia. AIDS.2005,19:1051 - 1058
  • 9Sekhar RV.Jahoor F.Pownall HJ,et al.Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome.Am J Clin Nutr,2005,81:1405-1410.
  • 10方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3069

共引文献8

同被引文献55

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部